We act for many of the world’s largest pharmaceutical companies, giving us broad and deep insights into the key trends and risks facing companies operating in the sector.
We advise on a wide range of complex cases, working with both national and international clients on high-profile and strategic matters. We have gathered significant and relevant experience of acting for leading companies in the life sciences sector on regulatory issues and we have built a track record of running a number of multi-jurisdictional matters. We also have a strong offering advising pharmaceuticals on transactions including M&A, collaborations and fundraising. Our clients include Novartis, Pfizer, Bayer, Merck, GSK, and Johnson & Johnson among many others.
News & insights
Blog Post: 25 January 2022
The Belgian Federal Agency for Medicines and Health Products (the FAMHP) has reviewed its procedure to remove or add patented therapeutic indications or dosage forms from the generic medicines'…
Blog Post: 21 January 2022
On 19 January 2022, the Unified Patent Court (UPC) came to life as an international organisation. Now, the preparatory phase for the official start of the UPC system can begin.
Blog Post: 05 January 2022
Vaccines With thanks to a huge global scientific effort, we now have several COVID-19 vaccines that have met the standards of safety and efficacy set by regulators.
Blog Post: 23 November 2021
In a new decision dated 24 September 2021, the Belgian Joint Commission's Chamber for Products for Human Use reversed its previous decision dated 27 November 2020, and now considers that oral nicotine…